Engineers Gate Manager LP Nuvation Bio Inc. Transaction History

Engineers Gate Manager LP

  • $4.27 Billion
  • Q2 2024

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
SELL
$0.96 - $1.53 $20,026 - $31,917
-20,861 Reduced 64.85%
11,306 $17,000
Q3 2023

Nov 14, 2023
BUY
$1.26 - $2.1 $23,548 - $39,246
18,689 Added 138.66%
32,167 $43,000
Q2 2023

Aug 14, 2023
SELL
$1.56 - $1.84 $7,665 - $9,041
-4,914 Reduced 26.72%
13,478 $24,000
Q1 2023

May 15, 2023
BUY
$1.6 - $2.48 $29,427 - $45,612
18,392 New
18,392 $30,000
Q3 2021

Nov 15, 2021
SELL
$7.78 - $10.0 $168,569 - $216,670
-21,667 Closed
0 $0
Q2 2021

Aug 16, 2021
BUY
$9.22 - $14.48 $199,769 - $313,738
21,667 New
21,667 $202,000

Others Institutions Holding NUVB

# of Institutions
152
Shares Held
123M
Call Options Held
9.7K
Put Options Held
6.5K
View Full List

About Nuvation Bio Inc.

NUVB Quotes by TradingView
  • Ticker NUVB
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 217,244,000
  • Market Cap $480M
  • Description
  • Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...
More about NUVB
Track This Portfolio

Track Engineers Gate Manager LP Portfolio

Follow Engineers Gate Manager LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

News

Stay updated on Engineers Gate Manager LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email